Tag: clinical trials
-
FDA Warns Dr. Goodenowe Health Center Founder Over Supplement Study Safety Concerns
FDA Issues Warning Over Supplement Trial Conduct The U.S. Food and Drug Administration (FDA) has issued a formal warning to the founder of the Dr. Goodenowe Restorative Health Center, based in Moose Jaw, Saskatchewan. The regulatory action follows an investigation into a recent clinical trial of the center’s dietary supplements, with authorities asserting that participant…
-
New Diagnostic Device Signals a Turning Point in Australia’s Deadliest Cancer Treatments
Australia’s Deadliest Cancer Faces a New Turning Point Pancreatic cancer remains one of Australia’s most lethal diseases, with late diagnoses often limiting treatment options and survival. A new diagnostic device, currently under clinical evaluation, promises to shift this trajectory by enabling earlier detection and more personalized treatment decisions. The device merges advanced biomarkers with imaging…
-
Microdosing Depression: As Effective as Coffee Daily
What the Latest Findings Say In recent years, researchers have explored whether tiny doses of psychedelics can ease depressive symptoms without triggering full-blown psychedelic experiences. A growing body of evidence suggests that microdosing may offer modest mood benefits for some people, bringing relief that, in studies, can resemble the daily lift many get from coffee.…
-
Kazia Therapeutics Reports Encouraging Early Signals from Paxalisib + Pembrolizumab in Late-Stage Metastatic TNBC
Overview of the Update Kazia Therapeutics (NASDAQ: KZIA) announced an interim clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage (Stage IV) metastatic triple-negative breast cancer (TNBC). The release underscores encouraging preliminary clinical responses observed to date, reinforcing interest in paxalisib as part of…
-
Kazia Therapeutics Unveils Encouraging Early Responses for Paxalisib in Late-Stage TNBC
Overview of the Phase 1b Study Kazia Therapeutics has announced encouraging preliminary clinical responses from its ongoing Phase 1b trial evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage, Stage IV triple-negative breast cancer (TNBC). The study explores paxalisib, an AKT inhibitor, as part of a multi-agent regimen designed to address the…
-
What the Science Really Says About Ivermectin for COVID-19
Intro: The ivermectin buzz in the early pandemic From the outset of the COVID-19 crisis, ivermectin attracted attention beyond its established role as a parasite medication. Early, small studies and social media chatter led some to claim it could prevent or treat COVID-19. Public interest surged even as major health bodies urged caution. Here’s what…
-
Ivermectin and COVID-19: What the Science Really Says
Understanding the ivermectin conversation during the COVID-19 pandemic As COVID-19 spread across the globe, interest in various treatments grew rapidly. Ivermectin, a long-standing antiparasitic drug, became a focal point of discussion far beyond its approved uses. Proponents cited laboratory studies and early clinical reports, while health authorities urged caution until robust evidence emerged. This tension…
-
What science actually says about ivermectin as a COVID-19 treatment
Introduction From the outset of the COVID-19 pandemic, multiple drugs were explored as potential treatments. Ivermectin, a drug long used to treat parasitic infections, drew attention early on as a possible COVID-19 remedy. Across media and social networks, claims that ivermectin could be a cure-all spread quickly. Here’s a clear, evidence-based look at what science…
-
Financial Factors in Cancer Clinical Trial Enrollment
Understanding the Link Between Finances and Trial Enrollment Recent research highlighted in the Journal of the National Comprehensive Cancer Network shows that a patient’s financial resources can influence enrollment in oncology clinical trials more strongly than traditional demographic factors. This finding underscores how economic realities—not just age, race, or education—shape access to experimental therapies that…
-
Financial Factors Drive Cancer Patients’ Enrollment in Clinical Trials More than Demographics
Introduction: Why Money Matters in Cancer Clinical Trials Enrollment in oncology clinical trials is a critical pathway to advancing cancer care. Recent evidence published in the Journal of the National Comprehensive Cancer Network indicates that financial resources play a larger role in whether patients enroll than traditional demographic characteristics such as age, race, or education.…